The FDA advances in multiple cancer types, and researchers assess potential impacts of funding freezes on cancer research.

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence application (sBLA) for an Opdivo (nivolumab) and Yervoy (ipilimumab ...

BMS’ Opdivo is approved in more than 65 countries. Credit: Amy Lutz/Shutterstock. The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...

Bristol Myers Squibb has won Food and Drug Administration priority review for its application seeking approval of the combination of its Opdivo and Yervoy cancer drugs for the early treatment of ...

Bristol Myers (BMY) Squibb announced that the U.S. FDA has accepted the supplemental biologics license application for Opdivo plus Yervoy as a potential first-line treatment option for adult and ...

NEW YORK – Bristol Myers Squibb said Monday that the US Food and Drug Administration has accepted its supplemental biologics license application (sBLA) seeking approval for the checkpoint inhibitor ...

Sunday’s Ambetter Health 400 NASCAR Cup Series event marks the 120th race hosted by Atlanta Motor Speedway in the series’ history. The 1.54-mile D-shaped oval racetrack featured an all new ...

After the predictably thrilling start to the NASCAR Cup Series last week at the Daytona 500, the racing world now shifts its attention to Atlanta Motor Speedway for the Ambetter Health 400.

Now that the heat of the Daytona 500 has fizzled, Cup drivers’ qualification for the Feb. 23 Ambetter Health 400 at Atlanta is in full swing. All eyes were on Ryan Blaney this morning as he led ...

Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of ...

Bristol Myers Squibb (BMS) has shared positive overall survival (OS) results from a late-stage study of its Opdivo (nivolumab) combination in non-small cell lung cancer (NSCLC). The phase 3 ...

Credit: JHVEPhoto / Shutterstock. Bristol Myers Squibb (BMS) has reported outcomes from the Phase III CheckMate -816 trial, indicating an overall survival (OS) benefit when Opdivo (nivolumab) is used ...